A child sitting on the shoulders of a man in a sunny room. Both are smilling and are flexing their biceps.

What is human health care (hhc)?

It's our way of life at Eisai – We give our first thoughts to patients and their families in order to guide our work and create breakthroughs for them.

An elderly lady sitting in a wheelchair holding the arm of a seated millenial man

hhc-Inspired Solutions for Patients Living with Neurological Disorders

We’re taking neurology to a whole new level.

Learn More Details
A nurse assisting an elderly female patient while she holds onto an adult walker

hhc-Inspired Solutions for Patients Living With Cancer

A world without cancer is getting closer every day.

Learn More Details

Our Global Mission

Our human health care mission is our corporate philosophy and the core of our business. Established in 1992, our hhc philosophy is a common value among employees worldwide. Spending time with patients and understanding their true needs has become the source of our innovation.

We have two therapeutic areas of focus: neurology and oncology.

Bringing human health care to Life

Breakthrough medicines are just the beginning. Our human health care philosophy inspires the ways in which we help improve the lives of patients, their families and caregivers. Discover how we’re supporting the communities we serve.

Leading with Integrity

What does it take to make meaningful contributions to patients and their families while observing the highest level of integrity? There are essential ways we maintain our ethical standards.

Explore Our U.S. Locations

See where Eisai breakthroughs happen, every step of the way from inception to distribution.

Meet Our Leadership Team

Meet the remarkable individuals who comprise our leadership team.

1%

To help us empathize fully with the people we serve, we spend 1% of our total business hours interacting with patients.

2B

That’s how many free DEC tablets Eisai has distributed to fight lymphatic filariasis, a neglected tropical disease transmitted by mosquitoes.

17

The number of Eisai U.S. compounds currently in clinical development (Phase 2 or later) and being evaluated for 30 indications.